The recently published Q1 financial statement from the Danish medtech company Coloplast is pretty much as could be expected, according to analyst Michael Friis Jørgensen from Alm. Brand Markets.
“There are no real surprises anywhere. Turnover is as expected, and Coloplast hangs on to the strong margins, as they have done for some time now. But it was completely as expected. So it is a bit of a non-event,” he tells Medwatch, adding: